Sign up USA
Proactive Investors - Run By Investors For Investors

Nektar Therapeutics surges on positive findings for its pain treatment

The candidate is designed to manage pain without high levels of euphoria that can lead to addiction with standard opioids.
Nektar Therapeutics surges on positive findings for its pain treatment
Nektar's candidate is a treatment for pain

Nektar Therapeutics (NASDAQ: NKTR ) shares surged almost 43% to US$22.13 in New York as it posted positive findings of a Phase 3 efficacy study of NKTR-181 - its opioid analgesic for treating pain.

The candidate is designed to manage pain without high levels of euphoria that can lead to addiction with standard opioids, and it met its primary and secondary endpoints.

NKTR-181 also demonstrated a favorable safety profile, Nektar said.

The Food and Drug Administration  (FDA) have granted the investigational medicine "fast track" designation for the treatment of moderate to severe chronic pain.

"The data from this efficacy study are extremely important because they demonstrate that NKTR-181 produces strong analgesia in patients suffering from chronic pain while NKTR-181 has also demonstrated significantly lower abuse potential than oxycodone in a human abuse potential study," said Martin Hale, the clinical investigator of the study and medical director at Gold Coast Research

He added: "The data for NKTR-181 suggest that it is a transformational pain medicine that could fundamentally change how we treat patients with chronic pain conditions."

Giles_55af4ddca6481.jpg


Register here to be notified of future NKTR Company articles
View full NKTR profile View Profile

Nektar Therapeutics Timeline

Related Articles

GW_Pharma.png
June 07 2017
Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy
picture of drug lab
February 07 2017
Amryt Pharma’s strategy to acquire, in-license and then develop drugs for hard to treat, so-called orphan diseases has been seeing some good progress.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use